Dergiler / Balkan Medical Journal / 2022 / Cilt: 39 - Sayı: 3

The Significance of Tumor Budding and Immunohistochemical Axl Expression in Gallbladder Adenocarcinomas

Sayfa
199–208
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It may be a good target to prevent tumor budding to reduce tumor invasion and metastasis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Tumor budding is a histopathological finding that is accepted as an indicator of epithelial-mesenchymal transformation in many solid tumors.
📊
Temel Bulgular & Veri:Study Design: A retrospective cross-sectional study Methods: Thirty-eight gallbladder cancer patients who underwent surgery between 2000 and 2017 were included in the study.
💡
Sonuç & Katkı:It may be a good target to prevent tumor budding to reduce tumor invasion and metastasis.
🔬Tür:Araştırma Makalesi
📍Kapsam:2000 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background: Tumor budding is a histopathological finding that is accepted as an indicator of epithelial-mesenchymal transformation in many solid tumors. Axl is a Receptor Tyrosine Kinase (RTK) family member and contributes to epithelial-mesenchymal transformation. It has been reported that its overexpression in various solid cancer cells is associated with a poor prognosis. It is claimed that Axl RTK may be the targeted molecule in treating some cancers due to its location in the cell membrane. Aims: To investigate the relationship between immunohistochemical (IHC) Axl expression with tumor budding on the histopathological level and their prognostic significance in patients with gallbladder carcinoma. Thus, it is aimed to contribute to the emergence of a molecular option for targeted, personalized therapy in these patients. Study Design: A retrospective cross-sectional study Methods: Thirty-eight gallbladder cancer patients who underwent surgery between 2000 and 2017 were included in the study. The expressions of Axl RTK in tumor tissues were evaluated by the IHC method. Demographic data (age, sex) of patients, histopathological features (size, growth pattern), tumor differentiation, pathological T staging, lymphovascular invasion, perineural and serosal invasion, surgical margin, tumor infiltrated lymphocyte, and tumor budding were examined. The tumor budding of the tumor was made according to the International Tumor Budding Consensus Conference and was classified as low (0-4 buds), intermediate (5-9 buds), high (≥ 10 buds). The relationship between clinical pathologic features, the survival rate, and Axl expression was analyzed with Person’s chi-square, Cox regression tests, and the Kaplan-Meier method. Results: Tumor budding was determined as low in 12, intermediate in 10, and high in 16 cases. The increased degree of tumor budding was associated with focal-diffuse Axl expression (p = 0.018), infiltrative growth patterns (p = 0.031), poor differentiation (p = 0.006), advanced pathological stage (p = 0.002), and serosal (p = 0.040), perineural (p = 0.008), and lymphovascular invasion (p < 0.0001). Overall survival time was shorter in patients with intermediate to high tumor budding compared with those with low tumor budding (p = 0.011). Conclusion: Axl expression appears to be associated with tumor budding capacity, which may be a poor prognostic criterion for patients with gallbladder cancer. It may be a good target to prevent tumor budding to reduce tumor invasion and metastasis.

🔖

Bu Makaleye Atıf Yap

ÖZ, Ö., ARGON, A., KEBAT, T., AKINCI, Ç. N., ÖZDEMİR, Ö. (2022). The Significance of Tumor Budding and Immunohistochemical Axl Expression in Gallbladder Adenocarcinomas. Balkan Medical Journal, Cilt: 39 - Sayı: 3, 199–208. https://ajindex.com/articles/460747

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Boutros C, Gary M, Baldwin K, Somasundar P. Gallbladder cancer: Past, present and an uncertain future. Surg Oncol. 2012;21:e183-e191. [CrossRef] 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. [CrossRef] 3. Wistuba II, Gazdar AF. Gallbladder cancer: Lessons from a rare tumour. Nat Rev Cancer. 2004;4:695-706. [CrossRef] 4. Stratification P, Patients GC. Gallbladder Cancer Patients. Published online 2020. 5. Li M, Lu J, Zhang F, et al. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett. 2014;355:201-209. [CrossRef] 6. Ma Z, Dong F, Li Z, et al. A Novel Prognostic Nomogram for Gallbladder Cancer after Surgical Resection: A Single-Center Experience. J Oncol. 2021; 6619149. [CrossRef] 7. Chen C, Geng Z, Shen H, et al. Long-term outcomes and prognostic factors in advanced gallbladder cancer: Focus on the advanced T stage. PLoS One. 2016;11: e0166361. [CrossRef] 8. Du W, Phinney NZ, Huang H, et al. AXL is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Mol Cancer Res. 2021;19:1412-1421. [CrossRef] 9. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014;33:1316-1324. [CrossRef] 10. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017; 1299-1311. [CrossRef] 11. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: Time to take notice. Mod Pathol. 2012;25:1315-1325. [CrossRef] 12. Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract. 2013;209:269-275. [CrossRef] 13. Gulluoglu M, Yegen G, Ozluk Y, et al. Tumor budding is independently predictive for lymph node involvement in early gastric cancer. Int J Surg Pathol. 2015;23:349-358. [CrossRef] 14. Leoncini E, Ricciardi W, Cadoni G, et al. Adult height and head and neck cancer: A pooled analysis within the INHANCE Consortium. Head Neck. 2014;36:1391. [CrossRef] 15. Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013;5: a009076. [CrossRef]